Skip to main content
Goutham Narla, MD, Medical Genetics, Ann Arbor, MI

GouthamNarlaMDPHD

Medical Genetics Ann Arbor, MI

Assistant Professor

Dr. Narla is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Narla's full profile

Already have an account?

Summary

  • I am physician scientist who specializes in the care of high risk cancer genetics patients. I run a translational cancer research laboratory focused on identifying and characterizing the genetic regulators of cancer development and progression and developing targeted molecular therapies to these alterations.

Education & Training

  • Mt Sinai SOMResidency, 2008 - 2012
  • Mount Sinai Hospital
    Mount Sinai HospitalFellowship, 2008 - 2011
  • Mt Sinai HospitalInternship, Medicine, 2006 - 2008
  • Mount Sinai School of Medicine
    Mount Sinai School of MedicinePh.D, Cancer Biology/Genetics, 2001 - 2006
  • Mount Sinai School of Medicine
    Mount Sinai School of MedicineClass of 2006, MD
  • Santa Clara UniversityBS, Biology/Economics, 1993 - 1997

Certifications & Licensure

  • MI State Medical License
    MI State Medical License 2018 - 2022
  • OH State Medical License
    OH State Medical License 2012 - 2021
  • NY State Medical License
    NY State Medical License 2008 - 2013

Awards, Honors, & Recognition

  • Harrington Scholarship 2012
  • Saul Horowitz, Jr. Memorial Award 2010
  • Humanism and Excellence in Teaching, Arnold P. Gold Foundation 2008
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • Targeted inhibition of the KLF6 splice variant KLF6SV1 suppresses prostate cancer growth and spread.  
    Narla G, DiFeo A, Yao S, Banno A, Hod E, Reeves H, Qiao RF, Camacho-Vanegas O, Levine A, Kirschenbaum A, Chan AM, Friedman SL, Martignetti JA, Cancer Res; 65:5761-8
  • Role of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination.  
    DiFeo A, Narla G, Hirschfeld J, Camacho-Vanegas O, Yao S, Rose S, Kalir T, Friedman SL, Buller RE, Martignetti JA, Clin Cancer Res; 12:3730-9
  • In vivo Regulation of p21 by the KLF6 Tumor Suppressor Gene in Mouse Liver and Human Hepatocellular Carcinoma.  
    Narla G, Kremer-Tal S, Matsumoto N, Zhao X, Yao S, Kelley K, Tarocchi M, Friedman SL, Oncogene; 26:4428-34
  • Join now to see all

Books/Book Chapters

Abstracts/Posters

  • PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation
    Goutham Narla, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • A 270 Kb Yeast Artificial Chromosome Containing Apolipoprotein(a) Appropriately Expresses in Transgenic Mice.
    Frazer KA, Narla G, Zhang JL, Rubin EM, Circulation ;90:624
  • KLF6 induces growth arrest in vivo by transcriptional upregulation of P21 independent of P53.
    Li D, Narla G, Kelley K, Ratziu V, Albrecht JK, Eng FJ, Friedman SL, Hepatology ;32:209A-A
  • Join now to see all

Lectures

  • Cancer Genetics: Past, Present, and Future. 
    Grand Rounds Seminar, Department of Medicine, Mount Sinai School of Medicine, New York, NY
  • The Role of Alternative Splicing in the Regulation of the KLF6 Tumor Suppressor Gene. 
    Fred Hutchinson Cancer Research Center, Seattle, WA
  • Personalized Medicine and Lung Cancer Treatment. 
    Charles R. Bronfman Institute for Personalized Medicine, Mount Sinai School of Medicine, New York
  • Join now to see all

Press Mentions

  • Case Western Reserve School of Medicine Awarded $1.6 Million for Undergraduate Research
    Case Western Reserve School of Medicine Awarded $1.6 Million for Undergraduate ResearchNovember 6th, 2018
  • Prototype Drug Uses Novel Mechanism to Treat Lung Cancers
    Prototype Drug Uses Novel Mechanism to Treat Lung CancersMay 16th, 2017
  • Rappta Therapeutics Appoints Sunjeet Sawhney as Chief Executive Officer
    Rappta Therapeutics Appoints Sunjeet Sawhney as Chief Executive OfficerSeptember 16th, 2021
  • Join now to see all

Professional Memberships

  • AACR
    Member

Other Languages

  • Spanish, French